Treatment of hyperprolactinemic amenorrheas with cabergoline;Tratamiento de amenorreas hiperprolactinemicas con cabergolina

Medicina

Volumn 57, Issue 6, 1997, Pages 657-661

  Fideleff, Hugo L ^a   Holland, Matilde E ^b   Chervin, Alberto ^c   Gurucharri, Carlos ^d   Sinai, Isaac ^e  

^a Hospital General De Agudos Teodoro Alvarez   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Hospital Oftalmologico Santa Lucia   (Argentina)

^d Hospital Bernardino Rivadavia   (Argentina)

^e HOSPITAL FRANCÉS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PROGESTERONE; PROLACTIN; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HUMAN; HYPERPROLACTINEMIA; MICROADENOMA; OVULATION; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING; ADOLESCENT; BLOOD; DRUG TOLERANCE; FEMALE; MULTICENTER STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMENORRHEA; BROMOCRIPTINE; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; PROLACTIN; TREATMENT OUTCOME;

EID: 0031463376     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Ho Ky, Thorner MO. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988; 36: 67-82.
2. Crosignani PG, Ferrari C. Dopaminergic treatments for hyperprolactinaemia. Bailleres Clin Obstet Gyencol 1990; 4: 441-55.
3. Webster J, Piscitelli G, Polli A, Ferrari C, Ismall I, Scanlon M. For the Cabergoline Comparative Study Group: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-9.
4. Siegel S. Estadistica no paramétrica. México DF; Editorial Trites, 1990.
5. Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Parachi A, et al. Long-lasting prolactin-lowering effect of Cabergoline. A new dopamine agonist in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63: 941-5.
6. Mattel AM, Ferrari C, Baroldi P, Cavioni V, Paracchi A, Galparoli C, et al. Prolactin lowering effect of acute and once weekly repetitive oral administration of Cabergolina at two dose levels in hyperpro-lactinemic patients. J Clin Endocrinol Metab 1988; 66: 193-8.
7. European Multicentre Study Group for Cabergoline in Lactation Inhibition: Single low dose randomised double multicentre study. BMJ 1991; 302: 1367-71.
8. Throner MO, Fluckinger E, Calne DB. Bromocriptine: a clinical and pharmacologic review. New York: Raven Press, 1980; p. 143-5.
9. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 221-35.
10. Fideleff HL, Boquete HR, Orlandi AM, Wainstein L, Holland ME. Evolución de prolactinomas en adolescentes. Medicina (Buenos Aires) 1991; 51: 121-6.